## JC03 Rec'd PCT/PTO 3 1 MAY 2005

·								
U.S. DEPARTMENT OF C	COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER						
	R TO THE UNITED STATES	KAWAMURA69						
DESIGNATED/ELECT	TED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
CONCERNING A FIL	ING UNDER 35 U.S.C. 371	10/536963						
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY CLAIMED						
PCT/JP03/015227 TITLE OF INVENTION	November 28, 2003	November 29, 2002						
	AMELIANAMINA MENDAMAN	CONTROLLON DISCUSSIONIONIONI DISCUSSIONI						
NOVEL MEDICAMENT FOR APPLICANT(S) FOR DO/EO/US	. AMELIORATING NEUROTRAN	SMISSION DYSFUNCTION DISEASES						
AFFLICANT(S) FOR DO/EO/05								
Ryoichi KAWAMURA et al.								
Applicant herewith submits to the Unite	ed States Designated/Elected Office (DO/EO/L	JS) the following items and other information:						
	of items concerning a filing under 35 U.S.C.							
	SEQUENT submission of items concerning a							
		S.C. 371(f) ) as soon as the application is in order for						
	able requirements of 35 U.S.C. 371(c) have be							
4. [X] The US has been elected (A								
	Application as filed (35 U.S.C. 371(c)(2))							
	equired only if not transmitted by the Internation	onal Bureau)						
·	· · · · · · · · · · · · · · · · · · ·							
<ul> <li>b. [X] has been communicated by the International Bureau.</li> <li>c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul>								
	ation of the International Application as filed							
a. [X] is attached hereto.	ation of the international repplication as fried	(33 0.5.0. 371(0)(2)).						
	submitted under 35 U.S.C. 154(d)(4).							
	f the International Application under PCT Arti	cle 19 (35 H S C 371(c)(3))						
	with (required only if not transmitted by the Int							
	cated by the International Bureau.	emational Buleau).						
	however, the time limit for making such amen	adments has NOT expired						
d. [X] have not been made:	_	idificits has NOT expired.						
		T Aminin 10 (25 H.S.C. 271(n)(2))						
9. [X ] An oath or declaration of the	ion of the amendments to the claims under PC	11 Afficie 19 (33 0.3.C. 371(c)(3)).						
		nami Evamination Danast under BCT Astiala 26						
(35 U.S.C. 371(c)(5)).	ion of the annexes to the international Frential	nary Examination Report under PCT Article 36						
4		,						
Items 11. to 16. below concern docum	ent(s) or information included:							
11. [ ] An Information Disclosure S	Statement under 37 CFR 1.97 and 1.98.							
12. [ ] An Assignment document fo	r recording. A separate cover sheet in complia	ance with 37 CFR 3.28 and 3.31 is included.						
13. [X ] A FIRST preliminary amen	dment.							
14. [X ] An Application Data Sheet	under 37 CFR 1.76.							
15. [ ] A substitute specification.								
16. [ ] A change of power of attorne	y and/or address letter.							
		with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.						
	ed International Application under 35 U.S.C.							
	language translation of the international appli	ication under 35 U.S.C. 154(d)(4)						
20. [X ] Other items or information:	rnational Application as filed.							
	est page of the International Publication (WO 2	2004/050114)						
	ternational Preliminary Examination Report. T							
[X] Formal drawings, 3 she								
[X ] Paper copy only of Sequence	uence Listing.							
[X ] Courtesy Copy of the Ir								
		Chemo-Sero-Therapeutic Research Institute whose address						
is 6-1, Okubo 1-chome	, Kumamoto-shi, Kumamoto-ken 860-8568 Ja	pan.						

## JC06 Rec'd PCT/PTO 31 MAY 2005

U.S. APPLICATION NO. (If			International Application No.				Attorney's Docket	No.	
20/	53696	PCT/JP03/015227				KAWAMURA 69			
21. The following fees are submitted:					CALCULATIONS PTO USE ONLY				
[xx] a) BASIC NATIONAL FEE (37 CFR 1.492(a))\$300.00									
[xx ] b) SEARCH FEE (37 CFR 1.492(b))									
US was International Searching Authority\$100.00									
[x ] Other ISR provided to USPTO\$400.00									
All other situations						\$ 9	00.00	1	
						ر س	00.00		
[XX ] c) EXAMINATION FEE (37 CFR 1.492 (c))									
[ ] IPEA/US gave wholly favorable IPER\$100.00									
[x ] All other situations\$200.00									
TOTAL OF ABOVE CALCULATIONS:								·	
Surcharge of \$130.00 for months from the earliest			ration later than [ ] 20 [	] 30		\$			
			f each additional 50 or fra	ction	RATE	ļ			
20 100		reof (ro	ound up to a whole number	r)	(1.492(g))				
39 - 100 CLAIMS	/50 Number Fil	ad	Number Extra	Data (1	X \$250.00 .492 (d-f))				
Total Claims	17- 20 =		Number Extra	X \$ 50	, ,,	\$			
Independent Claims	1- 3 =		X \$200			\$			
Multiple Dependent Clair	_			+ \$360		\$			
	( арр)		TOTAL OF ABOVE			\$900.	00 .		
Reduction of 1/2 for filing	by small entity, if app	olicable	. Applicant claims small	entity sta	tus. See 37	\$			
CFR 1.27.				- 64	IDTOTAL	£000	00		
Proofing for of \$120.00	for funishing the E	alich t	ranslation later than [ ]2		JBTOTAL =	\$900. \$	00		
months from the earliest				50 [ ] J	50	3			
					NAL FEE =	\$900.	00		
			21(h)). The assignment m			\$			
accompanied by an appro	priate cover sheet (3)	CFR3	3.28, 3.31). \$40.00 per prop TOTAL F		CLOSED =	\$900.0	00		
						A	Amount to be:	\$	
							refunded		
							charged	\$	
Payment Method (che	eck one only)								
a. [ ] A check in the	amount of \$		to cover the above f	ees is e	nclosed.				
	,	.,							
b. [X] Credit Card Pa	yment Form (PTO-	2038),	, authorizing payment in	n the an	ount of \$900	.00, is	attached.		
c. [ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ to cover the above fees.									
	ppy of this sheet is			J1 Ψ	<del></del> '	.0 0010	the above rees.		
Handling of Fee Deficiencies (check one only)									
[X ] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment									
to Deposit Account No. <b>02-4035</b> . A duplicate copy of this sheet is enclosed.									
[ ] If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account 02-4035. At this time, no authorization is given to charge any other fees.									
Nome we									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
Direct all correspondence to the address associated with						1		· \ \	
			Witti			1	/ / Xu	ww>	
CUSTOMER NUMBER 001444, which is currently:						SIGNATURE			
						Sheridan Neimark			
, , , ,						NAME			
						20,520			
							RATION NUMBER	₹	
FAX: (202) 737-3528  Date of this submission: May 31, 2005  SN:ccw									
Date of this sublitission. May 31, 2003						NY.CCW			

BROWDY AND NEIMARK Form BN-1390

(REVISED 2/03/05)

Page 2 of 2